Committed to making children and families healthier, Connecticut Children’s talented medical professionals are at the forefront of research and clinical trials. Such scientific inquiries change the future of children’s healthcare. From fundamental molecular science that helps us understand diseases at the most basic level, to motion studies designed to discover new ways for young athletes to avoid injuries and clinical trials that establish the most effective and efficient protocols for treating children, Connecticut Children’s is a research leader.
Connecticut Children’s commitment to research attracts some of the best talent in pediatrics. Research currently underway includes:
- Christine Finck, MD, is working to save more lives of premature infants by finding a way to engineer lung tissue. Compromised lungs, which she currently repairs surgically, are the chief problem for premature infants.
- Jeffrey Hyams, MD, is leading a first-of-its-kind five-year study on the effects of standardized therapy for children with ulcerative colitis. As part of this research, Dr. Hyams has enlisted 25 leading pediatric institutions throughout the United States and Canada to participate in the study.
- Juan Salazar, MD, physician-in-chief, is reducing rates of congenital syphilis in Haiti and Columbia by creating a program that performs rapid testing and treatment of pregnant women.
Investigators from Connecticut Children’s Medical Center and UConn Health are forging new partnerships for purposes of discovery and evaluation of biological mechanisms and agents for treatment of disease, improvement of health, and related fields of application as they affect children and youth.
Another important collaboration is Connecticut Children’s partnership with The Jackson Laboratory for Genomic Medicine in Farmington (JAX-GM) which allows us to garner the power of the human genome to provide families with new treatment options today and positions us to help find tomorrow’s cures. Connecticut Children’s clinicians have access to the JAX-GM federally certified Clinical Laboratory Improvement Amendments (CLIA) laboratory, which is capable of performing genomics analysis on biologic samples obtained from pediatric patients. This state-of-the-art testing capability, which is only available at a few of the nation’s largest children’s hospitals, can identify novel and personalized treatments for patients. This testing is one component of a larger collaborative program advancing precision medicine genomics-based treatments for children.